Slingshot members are tracking this event:

Merck (MRK) Presents Phase 3 Results Evaluating Inactivated Varicella Zoster Vaccine (VZV) V212 for the Prevention of Herpes Zoster (HZ) (Shingles)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 24, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Inactivated Varicella Zoster Virus Vaccine, V212, Herpes Zoster, Shingles